Hemostasis Device Market Size, Share, and Trends Analysis | Global | 2026-2032 | Includes: Hemostasis probes, Ligation devices, Sclerotherapy needles, and 1 more

The global hemostasis device market was valued at approximately $716 million in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 4.0 percent, reaching nearly $945 million by 2032.

This report covers hemostasis probes, ligation devices, sclerotherapy needles, and hemostasis powders, which together form the complete global hemostasis device market. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and analyzes market drivers and limiters, recent mergers and acquisitions, and technology trends. The report includes historical data from 2022 to 2024 and forecasts through 2032.

The scope reflects how hospitals and endoscopy centers evaluate product performance, combination therapies, and device innovation to improve outcomes and manage gastrointestinal bleeding effectively.

Market Overview

Hemostasis devices are used during gastrointestinal procedures to control and prevent bleeding. They include hemostasis probes, ligation clips and bands, sclerotherapy needles, and hemostasis powders. Collectively, these devices are essential for treating acute bleeding conditions, preventing post-procedure complications, and reducing the need for surgical intervention.

The global market continues to expand as patient demographics and procedural trends shift. The aging population, coupled with the increasing prevalence of diseases such as cirrhosis, hepatitis, and peptic ulcers, is driving demand for hemostatic interventions. As the incidence of gastrointestinal bleeding grows, healthcare providers are adopting a broader range of hemostatic solutions to improve safety and reduce procedure times.

One of the most significant developments influencing this market is the growing use of combination therapies. Studies have shown that procedures combining sclerotherapy needles with ligation clips or electrosurgical probes yield higher success rates and reduce the need for repeat interventions. Because both physicians and patients seek greater procedural efficiency and lower recurrence, adoption of these combination approaches continues to increase.

While pricing pressure and procurement dynamics continue to challenge manufacturers, rising procedure volumes, broader global access, and continuous technological improvement are expected to sustain long-term growth through 2032.

Market Drivers

Combination Therapy

Combination therapies that pair sclerotherapy needles with other hemostasis devices, such as ligation clips or electrosurgical probes, have been shown to be more effective than single-device procedures. By improving hemostatic success and reducing the need for follow-up treatments, these techniques support greater physician confidence and better patient outcomes.

This approach not only increases clinical adoption but also raises unit consumption per procedure. As hospitals move toward evidence-based care models, the preference for multi-device solutions will continue to drive unit sales growth.

Ligation Clips

The ligation clip segment is showing steady growth as more physicians prefer clips over ligation bands for the management of bleeding and the closure of mucosal defects. Clips are typically used in multiples per procedure, which raises total unit volumes. In addition, clip products command a price premium compared to bands, enhancing market value growth.

Ongoing product innovation in clip design and deployment systems has further strengthened this segment. Devices that provide better precision, rotation control, and deployment reliability are improving clinical efficiency and user confidence.

Demographic Factors

Population aging remains one of the strongest macroeconomic drivers in the hemostasis device market. Older adults experience higher rates of gastrointestinal bleeding caused by chronic liver disease, variceal conditions, and comorbidities that increase bleeding risk.

At the same time, unhealthy lifestyle trends-such as poor diet, alcohol consumption, and non-steroidal anti-inflammatory drug use-are contributing to rising cases of GI bleeding even among younger populations. The combined impact of these demographic and behavioral factors is expected to keep procedural demand high and sustain market expansion through 2032.

Growing Endoscopic Capabilities

As endoscopic technologies advance, physicians can manage a wider range of bleeding conditions without surgery. Modern endoscopy systems enable precise visualization of bleeding sites, while improved electrosurgical energy control supports faster coagulation. These capabilities increase the procedural success rate and drive higher utilization of hemostasis products across hospitals and ambulatory centers.

Market Limiters

Group Purchasing Organizations (GPOs)

Group purchasing organizations represent a major procurement channel for hospital equipment but also act as a restraint on market growth. GPOs consolidate demand and negotiate bulk pricing, which restricts manufacturers' ability to maintain higher ASPs.

They also limit hospitals' access to newer or niche products by focusing on standardized purchasing contracts. Vendors that depend heavily on GPO contracts may face slower price realization and reduced flexibility to expand their product portfolios within contracted facilities.

Drug Treatment Alternatives

Pharmaceutical companies continue to develop medications designed to prevent unexpected gastrointestinal bleeding. These therapies, particularly those targeting anticoagulant reversal or ulcer protection, may reduce the incidence of bleeding that requires procedural intervention.

If these drug therapies gain widespread adoption, they could reduce procedural volumes and slow demand for mechanical and electrosurgical hemostasis devices in certain cases.

Market Cannibalization

Within the broader hemostasis market, competition among device types limits overall value growth. For instance, ligation clips-though expanding rapidly-are capturing share from electrosurgical probes, heat probes, and argon plasma coagulation probes.

While these devices can be used in combination with clips, they are most effective when paired with sclerotherapy needles. As product preferences evolve, growth in one category can come at the expense of others, resulting in internal market shifts rather than net expansion.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, growth rates, units sold, and average selling prices.

Qualitative Coverage

Growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews that influence hemostasis device demand.

Time Frame

Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.

Data Sources

Primary interviews with endoscopists, purchasing managers, and industry executives; hospital procurement and regulatory databases; import and export data; and the iData Research internal database.

Method Note

Revenue estimates are modeled from units multiplied by ASP, validated with procedure volumes and utilization assumptions for each device type.

Markets Covered and Segmentation

• Hemostasis Device Market - Further Segmented Into:

Hemostasis Probe

Ligation Device

Sclerotherapy Needle

Hemostasis Powder

Competitive Analysis

Boston Scientific was the global leader in the hemostasis device market in 2025, maintaining strong positions across all major segments. The company's leadership in the ligation clip market was reinforced by the launch of the Resolution 360(TM) in 2016 and the upgraded Resolution 360(TM) ULTRA in 2020. Boston Scientific also markets the Gold Probe(TM) line as its flagship hemostasis probe, widely recognized for consistent performance and reliability.

Olympus Corporation ranked second in the market, supported by its broad product portfolio and long-standing expertise in gastrointestinal endoscopy. The company's leadership in the ligation device segment anchors its competitive strength. Olympus also remains the sole supplier in the heat probe market, with its HeatProbes(TM) product line used globally for endoscopic thermal coagulation.

Cook Medical held the third-largest share of the hemostasis device market. Its portfolio is led by the 6 Shooter(R) Universal Saeed(R) Multi-Ligator, which is widely used in endoscopic ligation procedures. The company also maintains a presence in ligation clips, electrosurgical probes, and sclerotherapy needles, ensuring a comprehensive offering across multiple endoscopic applications.

This competitive landscape is moderately concentrated, with the top three companies accounting for the majority of total market value. Regional competitors participate primarily in cost-sensitive markets, where pricing flexibility and local distribution relationships provide an advantage.

Technology and Practice Trends

Combination treatment protocols are becoming the standard approach for managing gastrointestinal bleeding, improving success rates and reducing rebleeding risk.

Single-use device adoption is increasing, particularly in hospitals focused on infection control and workflow efficiency.

Refinements in clip and probe design are improving procedural accuracy, rotation control, and deployment consistency.

Energy-based hemostasis technologies, including heat probes and argon plasma coagulation, remain key tools in conjunction with mechanical devices.

Training expansion and guideline alignment are enhancing physician familiarity with multi-device hemostasis procedures.

Powder-based hemostatic agents are gaining interest as adjunct tools for diffuse or difficult-to-access bleeding sites.

Together, these trends illustrate the market's shift toward integrated procedural solutions that balance safety, cost, and clinical efficiency.

Geography

This edition covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Methodology Appendix and Acronym Glossary

Why This Report

Where are the largest and fastest-growing opportunities within the global hemostasis device market

How are combination therapies and ligation clip adoption influencing market value

What factors are driving procedure volume growth in aging populations

How are drug treatments, GPO contracts, and internal device competition shaping pricing and share

Which manufacturers-Boston Scientific, Olympus, and Cook Medical-lead the market, and how are they differentiating their portfolios

What technological and procedural trends are expected to define next-generation hemostasis solutions

The Global Hemostasis Device Market Report from iData Research answers these questions with detailed procedure-based models, company share analysis, and pricing insights. Use it to plan product strategy, evaluate growth opportunities, and guide commercial and R&D decision-making.